Teva Pharmaceuticals USA recalls Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx onl
Recalled August 16, 2017 · FDA recall D-1058-2017 · Teva Pharmaceuticals USA
Hazard
Failed Moisture Limits: out of specification test results for water content obtained during stability testing. · FDA Class III
Units
2,880 cartons (30 unit dose blister pack per carton)
Sold at
Product distributed to OH, IL, PA, MI, VA and CT
Description
Failed Moisture Limits: out of specification test results for water content obtained during stability testing.
Product
Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15
Manufacturer(s)
Teva Pharmaceuticals USA
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →